Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Tuesday that its first quarter revenues rose 79 percent year over year, thanks to a corresponding 79 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended March 31, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $162.0 million, compared to $90.3 million a year earlier, and beating the average Wall Street analyst estimate of $153.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.